Form 4: Glaukos Director Leana Wen Receives RSU Grant

Glaukos Corp. Director Leana Wen was granted 623 restricted stock units, vesting in one year, as part of the company's director compensation policy.

Summary

• Leana Wen, a Director of Glaukos Corp. (GKOS), acquired 623 shares of common stock in the form of restricted stock units (RSUs).
• The transaction occurred on January 2, 2026, with a price of $0 per unit, typical for RSU grants.
• These RSUs were granted under the Issuer's Director Compensation Policy.
• The units are scheduled to vest in full on the one-year anniversary of the grant date, which is January 2, 2027.
• Upon vesting, the RSUs will be payable in an equivalent number of shares of Glaukos Corp.'s common stock.
• Following this transaction, Leana Wen beneficially owns 21,439 shares, which includes 2,731 unvested restricted stock units and other restricted stock units that have vested but whose delivery has been deferred.

Sentiment

Score: 7

Explanation: The filing reports a routine compensation event for a director, which is a positive for aligning management interests with shareholders but does not indicate any significant new operational or financial developments for the company.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value, as the value of the compensation is tied to the company's stock performance.
• This is a standard component of director compensation, indicating stable corporate governance practices.

Future Outlook

The 623 restricted stock units granted to Director Leana Wen are expected to vest in full on January 2, 2027, at which point they will be converted into an equivalent number of shares of Glaukos Corp. common stock.

Industry Context

The grant of restricted stock units to a director is a common practice in publicly traded companies across various industries. It serves as a form of equity compensation designed to attract and retain qualified board members while aligning their financial incentives with the long-term performance of the company and the interests of its shareholders.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of director compensation is a widely adopted practice among U.S. public companies, including those in the medical technology and ophthalmology sectors like Glaukos Corp.
• The vesting schedule of one year for these RSUs is also a common structure, promoting sustained engagement and long-term perspective from board members.
• Companies such as Alcon (ALC), Bausch + Lomb (BLCO), and Ivantis (acquired by New World Medical) often utilize similar equity-based compensation plans for their non-employee directors to foster alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 623 restricted stock units are scheduled to vest on January 2, 2027.

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted stock units to a director as part of their compensation, which is a standard practice to align director interests with long-term shareholder value. It does not provide new information that would alter the fundamental investment thesis for Glaukos Corp. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Glaukos, GKOS, Form 4, insider transaction, restricted stock units, RSU grant, director compensation, beneficial ownership